FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Pharma Mar, S.A. Stock AnalysisComprehensive stock analysis for Pharma Mar, S.A. (PHMMF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPHMMF
PHMMF
Pharma Mar, S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PHMMF
Home🔹Stocks🔹Pharma Mar, S.A.

Pharma Mar, S.A.

PHMMF•OTC

Pharma Mar, S.A.

PHMMF•OTC
Market cap
$1.53B
Sentiment

Your view on PHMMF

Mkt Cap
$1.53B
Sentiment
Your view
PHMMF
Pharma Mar, S.A.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
PHMMF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Pharma Mar, S.A.

Industry
Biotechnology
Sector
Healthcare
CEO
Jose Maria Fernandez Sousa-Faro
Headquarters
Avenida de los Reyes, 1, Madrid, ES
Industry
Biotechnology
Sector
Healthcare
CEO
Jose Maria Fernandez Sousa-Faro
Headquarters
Avenida de los Reyes, 1, Madrid, ES
Description

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News